Skip to content

Generic selectors
Correspondance exacte uniquement
Recherche dans le titre
Rechercher dans le contenu
Post Type Selectors
ELA International
ELA International
Secondary Navigation Menu
Menu
  • News
    • Archives News
  • Missions
    • Research funding
    • Support the families
    • To raise public awareness
    • International development
  • Organization
    • Our values
    • Our history
    • Our organization
    • ELA international’s members
    • The members
    • Advisory Board
  • Leukodystrophies
    • Introduction
    • Diseases
      • ALD/AMN
      • Undefined leukodystrophies
      • Canavan disease
      • Krabbe disease
      • Refsum disease
      • Alexander disease
      • MLC disease
      • MLD
      • PMD and other hypomyelinating leukodystrophies
      • Aicardi-Goutières syndrome
      • CACH syndrome
      • LTBL
    • The expert centers
      • Reference Center for Neurogenetic Diseases in Children and Adults
      • Reference Centre for Leukodystrophies in Robert-Debré
      • Reference Center for Leukodystrophies in Bicêtre
    • Make the expert centers known
  • Research
    • Scientific Committee
    • ELA Team
    • Main steps
    • Annual Call for Proposals
    • Clinical Trial FOA
    • Funded Research Projects
    • Clinical Studies
    • Leuconnect
      • Leuconnect
      • Studies online
      • Découvrez la messagerie de Leuconnect
    • Scientific events
      • Families/Researchers Meeting
      • Symposium
    • European Joint Programme on Rare Diseases (EJP Rare Diseases)
    • Additional documentation
    • Partners
  • Support
    • Become a donor
    • Mobilise
    • They support us
    • Become partner
    • Online shop
    • Contact
  • Français
  • English (UK)

The only innovative treatment for CALD will not be available in Europe : the incomprehension of ELA International!

UK – Lutte contre les Leucodystrophies l’incomprehension d’ELA International
2022-11-08

© ELA 2022